ArticleCureus2025
BRASH Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- BRASH Syndrome Unmasked: Digoxin Toxicity in the Setting of Cardiogenic Shock and Multiorgan Dysfunction.Case reports in critical care · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BRASH syndrome, characterized by Bradycardia, Renal Failure, AV (atrioventricular) nodal blockade, Shock, and Hyperkalemia, is a newly recognized clinical entity arising from the synergy between AV nodal blockade and hyperkalemia. This case reported an elderly female patient presented with dizziness and confusion and a complex medical history, including chronic kidney disease, atrial fibrillation, chronic obstructive pulmonary disease (COPD), and heart failure, with a medication regimen including Digoxin and Bisoprolol. Clinical examination revealed severe bradycardia and hypotension, necessitating high-flow oxygen. Diagnostic tests confirmed bradycardia, kidney and liver dysfunction, hyperkalemia, and acidosis, strongly suggesting BRASH syndrome, while other differentials were considered and ruled out. Treatment involved a temporary pacemaker, anti-hyperkalemic measures, and careful monitoring, leading to improved heart rate and resolution of symptoms. Further research is needed to establish consistent diagnostic criteria, but understanding the pathophysiology as hypoperfusion stemming from hyperkalemic potentiation of AV blocker activity can aid in quicker recognition and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.